Recipharm, a Swedish contract development and manufacturing organisation (CDMO), and LIDDS have jointly established an industrial manufacturing line to develop new prostate cancer drug, Liproca Depot.

LIDDS develops pharmaceutical products for the treatment of cancer and other diseases with its patented NanoZolid technology.

The manufacturing line, set up at Recipharm in Solna, Sweden, is dedicated to the production of the first product based on LIDDS’ technology.

Recipharm Solna facility general manager Torkel Gren said: “We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease.

"We are proud of having reached this important milestone in the development of a new product allowing improved therapy for a serious disease."

“This has been achieved by the hard work and close collaboration of experts at both LIDDS and Recipharm. LIDDS is a very innovative company and it has been extremely rewarding to work with the team.”

Clinical trial material has already been manufactured and the production facility is currently ready for future commercial development of Liproca Depot or other pharmaceutical formulations based on latest NanoZolid technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Adapted for Good Manufacturing Practice (GMP) production, the manufacturing line is industrialised according to a process invented by the company.

LIDDS chief executive officer Monica Wallter said: “With the successful manufacturing performed at Recipharm, LIDDS can offer licence agreements for Liproca Depot with the advantage of having validated production in place, saving both time and money for pharma companies.

“In addition, we now have an established manufacturing facility ready for other NanoZolid projects."